Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment.

van der Walt JS, Hong Y, Zhang L, Pfister M, Boulton DW, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2013 May 8;2:e42. doi: 10.1038/psp.2013.20.

2.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW.

Br J Clin Pharmacol. 2013 Sep;76(3):432-44. doi: 10.1111/bcp.12056.

3.

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW.

Clin Ther. 2011 Nov;33(11):1798-808. doi: 10.1016/j.clinthera.2011.09.011. Epub 2011 Oct 26.

PMID:
22030444
4.

Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.

Yang L, Li H, Li H, Bui A, Chang M, Liu X, Kasichayanula S, Griffen SC, Lacreta FP, Boulton DW.

Clin Ther. 2013 Aug;35(8):1211-1222.e2. doi: 10.1016/j.clinthera.2013.06.017. Epub 2013 Aug 2.

PMID:
23910664
5.

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW.

Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. Review.

PMID:
24105299
6.

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, Vandebosch A, Rusch S, Stieltjes H, Wajs E.

Clin Ther. 2015 Mar 1;37(3):610-628.e4. doi: 10.1016/j.clinthera.2014.12.013. Epub 2015 Feb 3.

PMID:
25659911
7.

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.

Boulton DW, Li L, Frevert EU, Tang A, Castaneda L, Vachharajani NN, Kornhauser DM, Patel CG.

Clin Pharmacokinet. 2011 Apr;50(4):253-65. doi: 10.2165/11584350-000000000-00000.

PMID:
21348538
8.

Asenapine pharmacokinetics in hepatic and renal impairment.

Peeters P, Bockbrader H, Spaans E, Dogterom P, Lasseter K, Marbury T, Gibson GL, de Greef R.

Clin Pharmacokinet. 2011 Jul;50(7):471-81. doi: 10.2165/11590490-000000000-00000.

PMID:
21651314
9.

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.

Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW.

Diabetes Obes Metab. 2013 Mar;15(3):280-3. doi: 10.1111/dom.12024. Epub 2012 Nov 19.

PMID:
23061428
10.
11.

Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.

Martin P, Oliver S, Gillen M, Marbury T, Millson D.

Clin Ther. 2015 Dec 1;37(12):2823-36. doi: 10.1016/j.clinthera.2015.09.016. Epub 2015 Oct 27.

PMID:
26519231
12.

Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.

Tirucherai GS, LaCreta F, Ismat FA, Tang W, Boulton DW.

Diabetes Obes Metab. 2016 Jul;18(7):678-84. doi: 10.1111/dom.12638.

PMID:
27291448
13.

The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.

Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B.

Br J Clin Pharmacol. 2002;53 Suppl 1:21S-30S.

14.
15.

Pharmacokinetics of sparfloxacin in patients with renal impairment.

Dorr MB, Johnson RD, Jensen B, Magner D, Marbury T, Talbot GH.

Clin Ther. 1999 Jul;21(7):1202-15.

PMID:
10463518
16.

Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.

Gerich JE, Bastien A.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):669-83. doi: 10.1586/ecp.11.54. Review.

PMID:
22111852
17.

Dapagliflozin: a review of its use in patients with type 2 diabetes.

Plosker GL.

Drugs. 2014 Dec;74(18):2191-209. doi: 10.1007/s40265-014-0324-3. Review.

PMID:
25389049
18.

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J.

Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.

19.

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.

Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T.

BMC Clin Pharmacol. 2011 Mar 17;11:3. doi: 10.1186/1472-6904-11-3.

20.

Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment.

Saleh S, Becker C, Frey R, Mück W.

Pulm Circ. 2016 Mar;6(Suppl 1):S75-85. doi: 10.1086/685647.

Supplemental Content

Support Center